In Mapping the LNP Frontier: The Quest for Better LNPs, Anna Rose Welch speaks with Örn Almarsson about the rapid evolution and remaining challenges of lipid nanoparticle delivery. Reflecting on his experience from Moderna to Axelyf, Almarsson highlights advances in LNP characterization, the untapped potential of targeted delivery across diverse cell types, and the ongoing need to improve potency while maintaining tolerability through “stealth” design. He also underscores a critical reality: even the most elegant science must align with physician adoption and payer priorities to truly make an impact, reinforcing Axelyf’s commitment to advancing both the science and strategy of RNA therapeutics.